131 related articles for article (PubMed ID: 31069401)
1. ApoAI-derived peptide increases glucose tolerance and prevents formation of atherosclerosis in mice.
Edmunds SJ; Liébana-García R; Nilsson O; Domingo-Espín J; Grönberg C; Stenkula KG; Lagerstedt JO
Diabetologia; 2019 Jul; 62(7):1257-1267. PubMed ID: 31069401
[TBL] [Abstract][Full Text] [Related]
2. Site-specific glycations of apolipoprotein A-I lead to differentiated functional effects on lipid-binding and on glucose metabolism.
Domingo-Espín J; Nilsson O; Bernfur K; Del Giudice R; Lagerstedt JO
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):2822-2834. PubMed ID: 29802959
[TBL] [Abstract][Full Text] [Related]
3. In vivo PET imaging with [(18)F]FDG to explain improved glucose uptake in an apolipoprotein A-I treated mouse model of diabetes.
Cochran BJ; Ryder WJ; Parmar A; Tang S; Reilhac A; Arthur A; Charil A; Hamze H; Barter PJ; Kritharides L; Meikle SR; Gregoire MC; Rye KA
Diabetologia; 2016 Sep; 59(9):1977-84. PubMed ID: 27193916
[TBL] [Abstract][Full Text] [Related]
4. A short peptide of the C-terminal class Y helices of apolipoprotein A-I has preserved functions in cholesterol efflux and in vivo metabolic control.
Edmunds SJ; Liébana-García R; Stenkula KG; Lagerstedt JO
Sci Rep; 2020 Oct; 10(1):18070. PubMed ID: 33093642
[TBL] [Abstract][Full Text] [Related]
5. TGR5 agonist ameliorates insulin resistance in the skeletal muscles and improves glucose homeostasis in diabetic mice.
Huang S; Ma S; Ning M; Yang W; Ye Y; Zhang L; Shen J; Leng Y
Metabolism; 2019 Oct; 99():45-56. PubMed ID: 31295453
[TBL] [Abstract][Full Text] [Related]
6. The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype.
Vinué Á; Navarro J; Herrero-Cervera A; García-Cubas M; Andrés-Blasco I; Martínez-Hervás S; Real JT; Ascaso JF; González-Navarro H
Diabetologia; 2017 Sep; 60(9):1801-1812. PubMed ID: 28608285
[TBL] [Abstract][Full Text] [Related]
7. Single injections of apoA-I acutely improve in vivo glucose tolerance in insulin-resistant mice.
Stenkula KG; Lindahl M; Petrlova J; Dalla-Riva J; Göransson O; Cushman SW; Krupinska E; Jones HA; Lagerstedt JO
Diabetologia; 2014 Apr; 57(4):797-800. PubMed ID: 24442447
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein E deficiency abrogates insulin resistance in a mouse model of type 2 diabetes mellitus.
Kawashima Y; Chen J; Sun H; Lann D; Hajjar RJ; Yakar S; Leroith D
Diabetologia; 2009 Jul; 52(7):1434-41. PubMed ID: 19436992
[TBL] [Abstract][Full Text] [Related]
9. Apolipoprotein A-I primes beta cells to increase glucose stimulated insulin secretion.
Nilsson O; Del Giudice R; Nagao M; Grönberg C; Eliasson L; Lagerstedt JO
Biochim Biophys Acta Mol Basis Dis; 2020 Mar; 1866(3):165613. PubMed ID: 31765698
[TBL] [Abstract][Full Text] [Related]
10. Discoidal HDL and apoA-I-derived peptides improve glucose uptake in skeletal muscle.
Dalla-Riva J; Stenkula KG; Petrlova J; Lagerstedt JO
J Lipid Res; 2013 May; 54(5):1275-82. PubMed ID: 23471027
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein A-I protection against atherosclerosis is dependent on genetic background.
Sontag TJ; Krishack PA; Lukens JR; Bhanvadia CV; Getz GS; Reardon CA
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):262-9. PubMed ID: 24334873
[TBL] [Abstract][Full Text] [Related]
12. Distinct metabolic and vascular effects of dietary triglycerides and cholesterol in atherosclerotic and diabetic mouse models.
Laplante MA; Charbonneau A; Avramoglu RK; Pelletier P; Fang X; Bachelard H; Ylä-Herttuala S; Laakso M; Després JP; Deshaies Y; Sweeney G; Mathieu P; Marette A
Am J Physiol Endocrinol Metab; 2013 Sep; 305(5):E573-84. PubMed ID: 23820620
[TBL] [Abstract][Full Text] [Related]
13. Dual Actions of Apolipoprotein A-I on Glucose-Stimulated Insulin Secretion and Insulin-Independent Peripheral Tissue Glucose Uptake Lead to Increased Heart and Skeletal Muscle Glucose Disposal.
Domingo-Espín J; Lindahl M; Nilsson-Wolanin O; Cushman SW; Stenkula KG; Lagerstedt JO
Diabetes; 2016 Jul; 65(7):1838-48. PubMed ID: 27207515
[TBL] [Abstract][Full Text] [Related]
14. Sequential induction of beta cell rest and stimulation using stable GIP inhibitor and GLP-1 mimetic peptides improves metabolic control in C57BL/KsJ db/db mice.
Pathak V; Vasu S; Gault VA; Flatt PR; Irwin N
Diabetologia; 2015 Sep; 58(9):2144-53. PubMed ID: 26048235
[TBL] [Abstract][Full Text] [Related]
15. HIV-based lentivirus-mediated vasoactive intestinal peptide gene delivery protects against DIO animal model of Type 2 diabetes.
Tasyurek HM; Eksi YE; Sanlioglu AD; Altunbas HA; Balci MK; Griffith TS; Sanlioglu S
Gene Ther; 2018 Jul; 25(4):269-283. PubMed ID: 29523882
[TBL] [Abstract][Full Text] [Related]
16. A novel selective VPAC2 agonist peptide-conjugated chitosan modified selenium nanoparticles with enhanced anti-type 2 diabetes synergy effects.
Zhao SJ; Wang DH; Li YW; Han L; Xiao X; Ma M; Wan DC; Hong A; Ma Y
Int J Nanomedicine; 2017; 12():2143-2160. PubMed ID: 28356733
[TBL] [Abstract][Full Text] [Related]
17. ApoA-IV improves insulin sensitivity and glucose uptake in mouse adipocytes via PI3K-Akt Signaling.
Li X; Wang F; Xu M; Howles P; Tso P
Sci Rep; 2017 Jan; 7():41289. PubMed ID: 28117404
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis.
Sherman CB; Peterson SJ; Frishman WH
Cardiol Rev; 2010; 18(3):141-7. PubMed ID: 20395699
[TBL] [Abstract][Full Text] [Related]
19. Glucagon-like peptide 1 receptor agonist ZP10A increases insulin mRNA expression and prevents diabetic progression in db/db mice.
Thorkildsen C; Neve S; Larsen BD; Meier E; Petersen JS
J Pharmacol Exp Ther; 2003 Nov; 307(2):490-6. PubMed ID: 12975499
[TBL] [Abstract][Full Text] [Related]
20. Low molecular weight fucoidan improves endoplasmic reticulum stress-reduced insulin sensitivity through AMP-activated protein kinase activation in L6 myotubes and restores lipid homeostasis in a mouse model of type 2 diabetes.
Jeong YT; Kim YD; Jung YM; Park DC; Lee DS; Ku SK; Li X; Lu Y; Chao GH; Kim KJ; Lee JY; Baek MC; Kang W; Hwang SL; Chang HW
Mol Pharmacol; 2013 Jul; 84(1):147-57. PubMed ID: 23658008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
